Bionime Corporation is a Taiwan-based company principally engaged in the manufacture and distribution of blood glucose monitoring products. The Company's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The Company distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
29/07/26	NT$58.30	+1.39%	146,565
28/07/26	NT$57.50	+0.35%	90,832
27/07/26	NT$57.30	+1.60%	56,316
24/07/26	NT$56.40	+1.81%	54,016
23/07/26	NT$55.40	-1.60%	66,098

End-of-day quote Taiwan S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Taiwan S.E. Other stock markets 29/07/2026			5-day change	1st Jan Change
58.30 ^TWD	+1.39%		+4.48%	-2.02%

07-13	Bionime Gets European Regulator's Certification for Glucose Monitoring System; Shares Jump 10%	MT
05-14	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	4.51B 139M 122M 114M 105M 196M 13.32B 201M 1.35B 529M 6.59B 522M 511M 22.78B	P/E 2024	-31x	P/E 2025	-22.2x
Enterprise Value	7.08B 218M 192M 179M 164M 308M 20.93B 315M 2.12B 831M 10.36B 820M 802M 35.8B	EV / Sales 2024	3.48x	EV / Sales 2025	3.58x
Free-Float	53.01%	Yield 2024 *	-	Yield 2025	-

07-13	Bionime Gets European Regulator's Certification for Glucose Monitoring System; Shares Jump 10%	MT
05-14	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-16	Bionime Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-13	Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/08/25	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
17/06/25	Bionime Corporation Approves Amendment to the Article of Incorporation	CI
12/05/25	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
10/04/25	Bionime Sees No Impact from US Reciprocal Tariffs	MT
12/11/24	Bionime Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
14/08/24	Bionime Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
08/08/24	Bionime Corporation Announces Financial Officer Changes	CI
28/06/24	Bionime Corporation Approves Cash Dividends, Payable on August 23, 2024	CI
10/05/24	Bionime Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

02/11/22	Bionime Announces the Introduction of Its Revolutionary iFree CGM for Diabetes Management Coming Soon	AQ
01/11/22	Bionime Corporation to Launch the Rightest iFree CGM, Proposed to Offer Precise and Accurate Blood Glucose Measurement and Monitoring	AQ
25/10/22	Bionime RIGHTEST iFree CGM System - An Innovative Approach to Keep Track of Every One Health	AQ
04/08/22	Bionime : Announcement of change the Globle Sales Division officer of the company.	PU
05/07/22	Bionime : Announcement of members of the first order audit committee of the Company.	PU

Bionime Corporation Stock

Stocks

4737

TW0004737002

Medical Equipment, Supplies & Distribution

Valuation: Bionime Corporation

Chart: Bionime Corporation

Latest news : Bionime Corporation

Press Releases: Bionime Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Bionime Corporation

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+1.39%
1 week	+4.48%
Current month	+4.86%
1 month	+2.28%
3 months	-7.46%
6 months	+5.42%
Current year	-2.02%

1 week	54.8	58.6
1 month	54.8	69.9
Current year	49.75	72.9
1 year	49.75	73.9
3 years	43.14	81.92
5 years	43.14	88.92
10 years	40	88.92

Manager	Title	Age	Since
Chun Mu Huang CEO	Chief Executive Officer	-	09/07/2010
Hui Chen Chen DFI	Director of Finance/CFO	-	06/11/2017
Zhi Long Yeh CTO	Chief Tech/Sci/R&D Officer	-	07/11/2018

Director	Title	Age	Since
Chun Mu Huang CHM	Chairman	-	14/04/2003
Tai Hsiung Chiang BRD	Director/Board Member	-	17/10/2007
Chien Hsing Lin BRD	Director/Board Member	-	28/06/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIONIME CORPORATION	+1.39%	+4.48%	-13.81%	-14.28%	137M
GUARDANT HEALTH, INC.	+0.31%	-4.43%	+232.57%	+269.22%	19.04B
BIOMÉRIEUX	-2.80%	+3.48%	-41.63%	-25.88%	10.07B
LANTHEUS HOLDINGS, INC.	-2.57%	-4.41%	+38.50%	+15.62%	6.68B
10X GENOMICS, INC.	-1.55%	-1.55%	+230.86%	-26.45%	5.97B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.31%	+4.14%	-15.57%	-20.65%	5.53B
CARIS LIFE SCIENCES, INC.	0.00%	+1.37%	-43.35%	-	4.41B
DIASORIN S.P.A.	+0.34%	+5.10%	-21.46%	-30.05%	4.26B
ANDON HEALTH CO., LTD.	-0.33%	-16.23%	+70.56%	+88.36%	4.15B
AUTOBIO DIAGNOSTICS CO., LTD.	+2.54%	+0.15%	-18.58%	-43.19%	2.69B
Average	-0.24%	-0.25%	+41.81%	+23.63%	6.3B
Weighted average by Cap.	-0.63%	-1.47%	+87.65%	+82.30%

	2024	2025
Net sales	1.93B 59.68M 52.44M 48.95M 44.92M 84.09M 5.72B 86.16M 580M 227M 2.83B 224M 219M 9.78B	1.84B 56.74M 49.86M 46.54M 42.71M 79.95M 5.43B 81.92M 552M 216M 2.69B 213M 208M 9.3B
Net income	-127M -3.93M -3.45M -3.22M -2.96M -5.53M -376M -5.67M -38.18M -14.93M -186M -14.74M -14.42M -643M	-180M -5.56M -4.89M -4.56M -4.19M -7.84M -533M -8.03M -54.11M -21.16M -264M -20.89M -20.43M -912M
Net Debt	2.78B 85.92M 75.49M 70.47M 64.67M 121M 8.23B 124M 836M 327M 4.07B 323M 316M 14.08B	2.57B 79.42M 69.79M 65.14M 59.79M 112M 7.61B 115M 772M 302M 3.76B 298M 292M 13.01B